ORG Wealth Partners LLC Purchases 291 Shares of Eli Lilly and Company (NYSE:LLY)

ORG Wealth Partners LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 21.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,630 shares of the company’s stock after buying an additional 291 shares during the period. Eli Lilly and Company accounts for approximately 0.4% of ORG Wealth Partners LLC’s portfolio, making the stock its 19th largest holding. ORG Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $1,258,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. ORG Partners LLC lifted its position in Eli Lilly and Company by 34.3% during the fourth quarter. ORG Partners LLC now owns 1,556 shares of the company’s stock valued at $1,202,000 after purchasing an additional 397 shares during the last quarter. Baker Tilly Wealth Management LLC raised its position in shares of Eli Lilly and Company by 20.9% during the 4th quarter. Baker Tilly Wealth Management LLC now owns 1,367 shares of the company’s stock valued at $1,055,000 after buying an additional 236 shares in the last quarter. Watts Gwilliam & Co. LLC lifted its holdings in shares of Eli Lilly and Company by 6.0% during the 4th quarter. Watts Gwilliam & Co. LLC now owns 1,688 shares of the company’s stock worth $1,306,000 after acquiring an additional 96 shares during the last quarter. Legacy Private Trust Co. grew its position in Eli Lilly and Company by 10.4% in the fourth quarter. Legacy Private Trust Co. now owns 9,616 shares of the company’s stock worth $7,424,000 after acquiring an additional 904 shares in the last quarter. Finally, Douglas Lane & Associates LLC raised its position in Eli Lilly and Company by 10.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 2,823 shares of the company’s stock valued at $2,179,000 after purchasing an additional 278 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on LLY. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Barclays cut their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, January 1st. Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Finally, Wolfe Research initiated coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,002.22.

Eli Lilly and Company Stock Up 0.2 %

Eli Lilly and Company stock traded up $1.70 during trading hours on Friday, hitting $788.92. 1,153,701 shares of the stock traded hands, compared to its average volume of 2,643,049. The company has a market cap of $748.93 billion, a PE ratio of 85.29, a PEG ratio of 2.99 and a beta of 0.41. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm’s 50-day moving average price is $786.48 and its two-hundred day moving average price is $860.65. Eli Lilly and Company has a one year low of $612.70 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 EPS. On average, research analysts forecast that Eli Lilly and Company will post 13.18 EPS for the current year.

Eli Lilly and Company announced that its board has approved a stock repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.76%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 64.86%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.